Moving fecal microbiota transplantation into the mainstream

Robert Orenstein, Cheryl L. Griesbach, John K. Dibaise

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.

Original languageEnglish (US)
Pages (from-to)589-598
Number of pages10
JournalNutrition in Clinical Practice
Volume28
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Clostridium Infections
Clostridium difficile
Patient Safety
Disease Management
Recurrence
Fecal Microbiota Transplantation
Therapeutics

Keywords

  • Clostridium difficile metagenome
  • fecal microbiota transplant
  • fecal transplant
  • microbiome

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Moving fecal microbiota transplantation into the mainstream. / Orenstein, Robert; Griesbach, Cheryl L.; Dibaise, John K.

In: Nutrition in Clinical Practice, Vol. 28, No. 5, 10.2013, p. 589-598.

Research output: Contribution to journalArticle

Orenstein, Robert ; Griesbach, Cheryl L. ; Dibaise, John K. / Moving fecal microbiota transplantation into the mainstream. In: Nutrition in Clinical Practice. 2013 ; Vol. 28, No. 5. pp. 589-598.
@article{6bdc52706455408d8710d947f8f4cab7,
title = "Moving fecal microbiota transplantation into the mainstream",
abstract = "In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.",
keywords = "Clostridium difficile metagenome, fecal microbiota transplant, fecal transplant, microbiome",
author = "Robert Orenstein and Griesbach, {Cheryl L.} and Dibaise, {John K.}",
year = "2013",
month = "10",
doi = "10.1177/0884533613497516",
language = "English (US)",
volume = "28",
pages = "589--598",
journal = "Nutrition in Clinical Practice",
issn = "0884-5336",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Moving fecal microbiota transplantation into the mainstream

AU - Orenstein, Robert

AU - Griesbach, Cheryl L.

AU - Dibaise, John K.

PY - 2013/10

Y1 - 2013/10

N2 - In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.

AB - In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.

KW - Clostridium difficile metagenome

KW - fecal microbiota transplant

KW - fecal transplant

KW - microbiome

UR - http://www.scopus.com/inward/record.url?scp=84884322584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884322584&partnerID=8YFLogxK

U2 - 10.1177/0884533613497516

DO - 10.1177/0884533613497516

M3 - Article

C2 - 23979974

AN - SCOPUS:84884322584

VL - 28

SP - 589

EP - 598

JO - Nutrition in Clinical Practice

JF - Nutrition in Clinical Practice

SN - 0884-5336

IS - 5

ER -